drugset
drugset / Trial / NCT06437171

FeNO as a Marker of Allergic Reactions to OFC and Response of OMA Treatment in Multiple FA

NCT06437171 ↗

Phase 4 Active not recruiting 20 enrolled AAADRS Clinical Research Center
NaSingle-groupOpen-labelTreatment

Summary

This is a Phase IV, open-label, single-center study to evaluate the change in FeNO as a marker of clinical response to OMA in participants with multiple FA.

Timeline

Start
2024-06-03
Primary completion
2026-07
Completion
2026-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Omalizumab Monoclonal antibody — Other

Indications

food allergy